Active, Not Recruiting
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer - CA209-7MA
Uppdaterad:
9 december, 2024
|
ClinicalTrials.gov
Kön
Åldersintervall
Active, Not Recruiting
Inclusion Criteria: - Diagnosis of stage IV Non-Small Cell Lung Cancer (NSCLC) (histologically or cytologically confirmed stage), without known Epidermal Growth Factor Receptor (EGFR)- or Anaplastic Lymphoma Kinase (ALK)-alterations (according to label approved by EU) - Decision to initiate a first-line treatment with nivolumab plus ipilimumab combined with two cycles of chemotherapy for the treatment of NSCLC according to the German label has been made independently of the study Exclusion Criteria: - Current primary diagnosis of a cancer other than NSCLC that requires systemic or other treatment - Participants with known EGFR- or ALK-alterations Other protocol-defined inclusion/exclusion criteria apply
Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information
466-SE-2100058